Patent ID: 8921318
Filing Date: 2014-12-30
Classification: A61K,A61P,C07K

Abstract:
1. A method for the treatment of hormone-dependent cancers comprising a first period and a second period; wherein hormonal castration as indicated by a testosterone blood level of 1.2 ng/mL or lower is not maintained during the second period, comprising: a) administering to a patient in need thereof an initial dose of at least one LHRH analogue over the first period, the total amount of LHRH analogue in the dose being sufficient to effect hormonal castration such that a testosterone blood level is less than 1.2 ng/ml, wherein the initial dose is 65 mg to 300 mg, followed by b) administration of a maintenance dose of at least one LHRH antagonist in an amount of from 1 to 65 mg over the second period which comprises at least 30 days, the total amount of LHRH antagonist in the maintenance dose being insufficient to achieve or maintain a testosterone blood level of 1.2 ng/mL or lower, and wherein at least temporarily the patient's individual blood level of Prostate Specific Antigen (PSA) is equal to or below 20 ng/ml.